Diagnosis and Management of Early Stages of ALD

Abstract

Early forms of alcohol-associated liver disease (ALD) include different stages in the progression of compensated liver disease ranging from steatosis to steatohepatitis and fibrosis. ALD has been classically diagnosed at advanced stages more frequently than other liver diseases. This fact probably contributed to the scarcity of studies on early forms of ALD. Recent studies have investigated the prevalence of early ALD in the general population and have described the natural history of alcohol-induced steatosis and fibrosis, which have been linked to worse prognosis compared with early stages of other chronic liver diseases. In addition, studies on screening and early diagnosis of ALD in at-risk populations have shown that these strategies allow early detection and intervention. Of note, up to 28% of the United States population has concurrent alcohol use and metabolic syndrome, and estimated prevalence of advanced fibrosis among heavy drinkers with metabolic syndrome has increased from 3% in the 1990s to more than 10% in the 2010s. Therefore, new challenges and treatment opportunities will emerge for patients with ALD. In this review, we provide an overview of the state of the art in early ALD, focusing on natural history, diagnosis, and management, and provide insights into future perspectives.

Keywords

screening - fibrosis - steatosis - metabolic - alcohol

Publication History

Accepted Manuscript online:
18 February 2025

Article published online:
25 March 2025

• References

• 1 Devarbhavi H, Asrani SK, Arab JP, Nartey YA, Pose E, Kamath PS. Global burden of liver disease: 2023 update. J Hepatol 2023; 79 (02) 516-537
• 2 Stein E, Cruz-Lemini M, Altamirano J. et al. Heavy daily alcohol intake at the population level predicts the weight of alcohol in cirrhosis burden worldwide. J Hepatol 2016; 65 (05) 998-1005
• 3 Jinjuvadia R, Liangpunsakul S. Translational Research and Evolving Alcoholic Hepatitis Treatment Consortium. Trends in alcoholic hepatitis-related hospitalizations, financial burden, and mortality in the United States. J Clin Gastroenterol 2015; 49 (06) 506-511
• 4 Sepanlou SG, Safiri S, Bisignano C. et al; GBD 2017 Cirrhosis Collaborators. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol 2020; 5 (03) 245-266
• 5 Rinella ME, Lazarus JV, Ratziu V. et al; NAFLD Nomenclature Consensus Group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol 2023; 79 (06) 1542-1556
• 6 Ciardullo S, Carbone M, Invernizzi P, Perseghin G. Exploring the landscape of steatotic liver disease in the general US population. Liver Int 2023; 43 (11) 2425-2433
• 7 Kalligeros M, Vassilopoulos A, Vassilopoulos S, Victor DW, Mylonakis E, Noureddin M. Prevalence of steatotic liver disease (MASLD, MetALD, and ALD) in the United States: NHANES 2017-2020. Clin Gastroenterol Hepatol 2024; 22 (06) 1330-1332.e4
• 8 Lee BP, Dodge JL, Terrault NA. National prevalence estimates for steatotic liver disease and subclassifications using consensus nomenclature. Hepatology 2024; 79 (03) 666-673
• 9 Yang AH, Tincopa MA, Tavaglione F. et al. Prevalence of steatotic liver disease, advanced fibrosis and cirrhosis among community-dwelling overweight and obese individuals in the USA. Gut 2024; 73 (12) 2045-2053
• 10 Gawrieh S, Vilar-Gomez E, Woreta TA. et al. Prevalence of steatotic liver disease, MASLD, MetALD and significant fibrosis in people with HIV in the United States. Aliment Pharmacol Ther 2024; 59 (05) 666-679
• 11 Shah ND, Ventura-Cots M, Abraldes JG. et al. Alcohol-related liver disease is rarely detected at early stages compared with liver diseases of other etiologies worldwide. Clin Gastroenterol Hepatol 2019; 17 (11) 2320-2329.e12
• 12 Schomerus G, Lucht M, Holzinger A, Matschinger H, Carta MG, Angermeyer MC. The stigma of alcohol dependence compared with other mental disorders: a review of population studies. Alcohol Alcohol 2011; 46 (02) 105-112
• 13 Scholten K, Twohig P, Samson K. et al. You can't handle the truth! Comparing serum phosphatidylethanol to self-reported alcohol intake in chronic liver disease patients. Dig Liver Dis 2024; 56 (07) 1215-1219
• 14 Nasr P, Wester A, Ekstedt M. et al. Misclassified alcohol-related liver disease is common in presumed metabolic dysfunction-associated steatotic liver disease and highly increases risk for future cirrhosis. Clin Gastroenterol Hepatol 2024; 22 (05) 1048-1057.e2
• 15 Staufer K, Huber-Schönauer U, Strebinger G. et al. Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in presumed non-alcoholic fatty liver disease. J Hepatol 2022; 77 (04) 918-930
• 16 Constant A, Sherlaw W, Kovess-Masfety V. Seeking mental health care from private health practitioners among individuals with alcohol dependence/abuse; results from a study in the French general population. Alcohol 2017; 59: 1-6
• 17 Jophlin LL, Singal AK, Bataller R. et al. ACG clinical guideline: alcohol-associated liver disease. Am J Gastroenterol 2024; 119 (01) 30-54
• 18 You M, Fischer M, Deeg MA, Crabb DW. Ethanol induces fatty acid synthesis pathways by activation of sterol regulatory element-binding protein (SREBP). J Biol Chem 2002; 277 (32) 29342-29347
• 19 Mackowiak B, Fu Y, Maccioni L, Gao B. Alcohol-associated liver disease. J Clin Invest 2024; 134 (03) e176345
• 20 McKim SE, Gäbele E, Isayama F. et al. Inducible nitric oxide synthase is required in alcohol-induced liver injury: studies with knockout mice. Gastroenterology 2003; 125 (06) 1834-1844
• 21 Parker R, Aithal GP, Becker U. et al; WALDO study group. Natural history of histologically proven alcohol-related liver disease: a systematic review. J Hepatol 2019; 71 (03) 586-593
• 22 Hagström H, Thiele M, Roelstraete B, Söderling J, Ludvigsson JF. Mortality in biopsy-proven alcohol-related liver disease: a population-based nationwide cohort study of 3453 patients. Gut 2021; 70 (01) 170-179
• 23 Deleuran T, Grønbaek H, Vilstrup H, Jepsen P. Cirrhosis and mortality risks of biopsy-verified alcoholic pure steatosis and steatohepatitis: a nationwide registry-based study. Aliment Pharmacol Ther 2012; 35 (11) 1336-1342
• 24 Hagström H, Thiele M, Sharma R. et al. Cardiovascular outcomes in patients with biopsy-proven alcohol-related liver disease. Clin Gastroenterol Hepatol 2023; 21 (07) 1841-1853.e12
• 25 Edmondson HA, Peters RL, Frankel HH, Borowsky S. The early stage of liver injury in the alcoholic. Medicine (Baltimore) 1967; 46 (02) 119-129
• 26 Gao H, Jiang Y, Zeng G. et al. Cell-to-cell and organ-to-organ crosstalk in the pathogenesis of alcohol-associated liver disease. eGastroenterology 2024; 2 (04) e100104
• 27 Lackner C, Spindelboeck W, Haybaeck J. et al. Histological parameters and alcohol abstinence determine long-term prognosis in patients with alcoholic liver disease. J Hepatol 2017; 66 (03) 610-618
• 28 Tian C, Stokowski RP, Kershenobich D, Ballinger DG, Hinds DA. Variant in PNPLA3 is associated with alcoholic liver disease. Nat Genet 2010; 42 (01) 21-23
• 29 Stickel F, Buch S, Lau K. et al. Genetic variation in the PNPLA3 gene is associated with alcoholic liver injury in Caucasians. Hepatology 2011; 53 (01) 86-95
• 30 Whitfield JB, Schwantes-An TH, Darlay R. et al; GenomALC Consortium. A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers. J Hepatol 2022; 76 (02) 275-282
• 31 Buch S, Stickel F, Trépo E. et al. A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis. Nat Genet 2015; 47 (12) 1443-1448
• 32 Åberg F, Helenius-Hietala J, Puukka P, Jula A. Binge drinking and the risk of liver events: a population-based cohort study. Liver Int 2017; 37 (09) 1373-1381
• 33 Surial B, Bertholet N, Daeppen JB. et al; The Swiss Hiv Cohort Study. The impact of binge drinking on mortality and liver disease in the Swiss HIV cohort study. J Clin Med 2021; 10 (02) 1-12
• 34 Hagström H. Alcohol, smoking and the liver disease patient. Best Pract Res Clin Gastroenterol 2017; 31 (05) 537-543
• 35 Petermann-Rocha F, Zhou Z, Mathers JC. et al. Diet modifies the association between alcohol consumption and severe alcohol-related liver disease incidence. Nat Commun 2024; 15 (01) 6880
• 36 Naveau S, Giraud V, Borotto E, Aubert A, Capron F, Chaput JC. Excess weight risk factor for alcoholic liver disease. Hepatology 1997; 25 (01) 108-111
• 37 Whitfield JB, Masson S, Liangpunsakul S. et al; GenomALC Consortium. Obesity, diabetes, coffee, tea, and cannabis use alter risk for alcohol-related cirrhosis in 2 large cohorts of high-risk drinkers. Am J Gastroenterol 2021; 116 (01) 106-115
• 38 Ding C, Ng Fat L, Britton A. et al. Binge-pattern alcohol consumption and genetic risk as determinants of alcohol-related liver disease. Nat Commun 2023; 14 (01) 8041
• 39 Singal AK, Arsalan A, Dunn W. et al. Alcohol-associated liver disease in the United States is associated with severe forms of disease among young, females and Hispanics. Aliment Pharmacol Ther 2021; 54 (04) 451-461
• 40 Ahn JC, Wi CI, Buryska S. et al. Disproportionate increases in alcohol-associated hepatitis incidence in women and individuals of low socioeconomic status: a population-based study using the Rochester epidemiology project database. Hepatol Commun 2023; 7 (06) e0160
• 41 Lee EY, Nguyen VH, Cheung R, Nguyen MH. Trends of chronic liver diseases by income level and socioeconomic factors in the United States: a population-based study. Aliment Pharmacol Ther 2024; 60 (10) 1374-1387
• 42 Pose E, Pera G, Torán P. et al. Interaction between metabolic syndrome and alcohol consumption, risk factors of liver fibrosis: a population-based study. Liver Int 2021; 41 (07) 1556-1564
• 43 Lee BP, Dodge JL, Mack WJ, Leventhal AM, Terrault NA. National trends in alcohol use, metabolic syndrome, and liver disease from 1999 to 2018. Ann Intern Med 2023; 176 (06) 879-882
• 44 Sripongpun P, Kaewdech A, Udompap P, Kim WR. Characteristics and long-term mortality of individuals with MASLD, MetALD, and ALD, and the utility of SAFE score. JHEP Rep Innov Hepatol 2024; 6 (10) 101127
• 45 Schneider CV, Schneider KM, Raptis A, Huang H, Trautwein C, Loomba R. Prevalence of at-risk MASH, MetALD and alcohol-associated steatotic liver disease in the general population. Aliment Pharmacol Ther 2024; 59 (10) 1271-1281
• 46 Israelsen M, Torp N, Johansen S. et al; GALAXY consortium. Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study. Lancet Gastroenterol Hepatol 2024; 9 (03) 218-228
• 47 Oh R, Kim S, Cho SH. et al. Metabolic dysfunction-associated steatotic liver disease and all-cause and cause-specific mortality. Diabetes Metab J 2025; 49 (01) 80-91
• 48 Kwak M, Kim HS, Jiang ZG. et al. MASLD/MetALD and mortality in individuals with any cardio-metabolic risk factor: a population-based study with 26.7 years of follow-up. Hepatology 2025; 81 (01) 228-237
• 49 Tamaki N, Kimura T, Wakabayashi SI. et al. Long-term clinical outcomes in steatotic liver disease and incidence of liver-related events, cardiovascular events and all-cause mortality. Aliment Pharmacol Ther 2024; 60 (01) 61-69
• 50 Marti-Aguado D, Calleja JL, Vilar-Gomez E. et al. Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease. J Hepatol 2024; 81 (06) 930-940
• 51 Sogabe M, Okahisa T, Kagawa M. et al. The association between alcohol consumption and cardiometabolic factors and liver fibrosis in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction and alcohol-associated liver disease. Aliment Pharmacol Ther 2024; 60 (11-12): 1587-1598
• 52 Israelsen M, Rungratanawanich W, Thiele M, Liangpunsakul S. Non-invasive tests for alcohol-associated liver disease. Hepatology 2024; 80 (06) 1390-1407
• 53 Ventura-Cots M, Argemi J, Jones PD. et al. Clinical, histological and molecular profiling of different stages of alcohol-related liver disease. Gut 2022; 71 (09) 1856-1866
• 54 Mueller S, Englert S, Seitz HK. et al. Inflammation-adapted liver stiffness values for improved fibrosis staging in patients with hepatitis C virus and alcoholic liver disease. Liver Int 2015; 35 (12) 2514-2521
• 55 Knight M, Nelson-Piercy C, Kurinczuk JJ, Spark P, Brocklehurst P. UK Obstetric Surveillance System. A prospective national study of acute fatty liver of pregnancy in the UK. Gut 2008; 57 (07) 951-956
• 56 Gratacós-Ginès J, Avitabile E, Montironi C. et al. Alcoholic foamy degeneration, an entity resembling alcohol-associated hepatitis: diagnosis, prognosis, and molecular profiling. Clin Gastroenterol Hepatol 2024; 22 (04) 768-777.e8
• 57 Poynard T, Ratziu V, Naveau S. et al. The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Comp Hepatol 2005; 4: 10
• 58 Bedogni G, Bellentani S, Miglioli L. et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 2006; 6: 33
• 59 Bedogni G, Kahn HS, Bellentani S, Tiribelli C. A simple index of lipid overaccumulation is a good marker of liver steatosis. BMC Gastroenterol 2010; 10: 98
• 60 Lee JH, Kim D, Kim HJ. et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis 2010; 42 (07) 503-508
• 61 Kotronen A, Peltonen M, Hakkarainen A. et al. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology 2009; 137 (03) 865-872
• 62 Hernaez R, Lazo M, Bonekamp S. et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology 2011; 54 (03) 1082-1090
• 63 Kromrey ML, Ittermann T, Berning M. et al. Accuracy of ultrasonography in the assessment of liver fat compared with MRI. Clin Radiol 2019; 74 (07) 539-546
• 64 Dasarathy S, Dasarathy J, Khiyami A, Joseph R, Lopez R, McCullough AJ. Validity of real time ultrasound in the diagnosis of hepatic steatosis: a prospective study. J Hepatol 2009; 51 (06) 1061-1067
• 65 Noureddin M, Lam J, Peterson MR. et al. Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. Hepatology 2013; 58 (06) 1930-1940
• 66 Chen J, Martin-Mateos R, Li J. et al. Multiparametric magnetic resonance imaging/magnetic resonance elastography assesses progression and regression of steatosis, inflammation, and fibrosis in alcohol-associated liver disease. Alcohol Clin Exp Res 2021; 45 (10) 2103-2117
• 67 Mennesson N, Dumortier J, Hervieu V. et al. Liver steatosis quantification using magnetic resonance imaging: a prospective comparative study with liver biopsy. J Comput Assist Tomogr 2009; 33 (05) 672-677
• 68 Thomsen C, Becker U, Winkler K, Christoffersen P, Jensen M, Henriksen O. Quantification of liver fat using magnetic resonance spectroscopy. Magn Reson Imaging 1994; 12 (03) 487-495
• 69 Thiele M, Rausch V, Fluhr G. et al. Controlled attenuation parameter and alcoholic hepatic steatosis: diagnostic accuracy and role of alcohol detoxification. J Hepatol 2018; 68 (05) 1025-1032
• 70 Atkinson SR, Grove JI, Liebig S. et al. In severe alcoholic hepatitis, serum keratin-18 fragments are diagnostic, prognostic, and theragnostic biomarkers. Am J Gastroenterol 2020; 115 (11) 1857-1868
• 71 Li M, He Y, Zhou Z. et al. MicroRNA-223 ameliorates alcoholic liver injury by inhibiting the IL-6-p47^phox-oxidative stress pathway in neutrophils. Gut 2017; 66 (04) 705-715
• 72 Chen YP, Jin X, Xiang Z, Chen SH, Li YM. Circulating microRNAs as potential biomarkers for alcoholic steatohepatitis. Liver Int 2013; 33 (08) 1257-1265
• 73 Sterling RK, Lissen E, Clumeck N. et al; APRICOT Clinical Investigators. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43 (06) 1317-1325
• 74 Wai CT, Greenson JK, Fontana RJ. et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38 (02) 518-526
• 75 Serra-Burriel M, Juanola A, Serra-Burriel F. et al; LiverScreen Consortium Investigators. Development, validation, and prognostic evaluation of a risk score for long-term liver-related outcomes in the general population: a multicohort study. Lancet 2023; 402 (10406): 988-996
• 76 Kjaergaard M, Lindvig KP, Thorhauge KH. et al. Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease. J Hepatol 2023; 79 (02) 277-286
• 77 Thiele M, Madsen BS, Hansen JF, Detlefsen S, Antonsen S, Krag A. Accuracy of the enhanced liver fibrosis test vs FibroTest, elastography, and indirect markers in detection of advanced fibrosis in patients with alcoholic liver disease. Gastroenterology 2018; 154 (05) 1369-1379
• 78 Nguyen-Khac E, Thiele M, Voican C. et al. Non-invasive diagnosis of liver fibrosis in patients with alcohol-related liver disease by transient elastography: an individual patient data meta-analysis. Lancet Gastroenterol Hepatol 2018; 3 (09) 614-625
• 79 Berzigotti A, Tsochatzis E, Boursier J. et al; European Association for the Study of the Liver. Electronic address: [e-mail], European Association for the Study of the Liver. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis—2021 update. J Hepatol 2021; 75 (03) 659-689
• 80 Hsu C, Caussy C, Imajo K. et al. Magnetic resonance vs transient elastography analysis of patients with nonalcoholic fatty liver disease: a systematic review and pooled analysis of individual participants. Clin Gastroenterol Hepatol 2019; 17 (04) 630-637.e8
• 81 Hetland LE, Kronborg TM, Thing M. et al. Suboptimal diagnostic accuracy of ultrasound and CT for compensated cirrhosis: evidence from prospective cohort studies. Hepatol Commun 2023; 7 (09) e0231
• 82 Li M, Lin Y, Yu H. et al. The steatosis-associated fibrosis estimator (SAFE) outperformed the FIB-4 score in screening the population for liver disease. Ann Hepatol 2024; 29 (05) 101516
• 83 Graupera I, Thiele M, Serra-Burriel M. et al; Investigators of the LiverScreen Consortium. Low accuracy of FIB-4 and NAFLD fibrosis scores for screening for liver fibrosis in the population. Clin Gastroenterol Hepatol 2022; 20 (11) 2567-2576.e6
• 84 Parés A, Deulofeu R, Giménez A. et al. Serum hyaluronate reflects hepatic fibrogenesis in alcoholic liver disease and is useful as a marker of fibrosis. Hepatology 1996; 24 (06) 1399-1403
• 85 Lieber CS, Weiss DG, Paronetto F. Veterans Affairs Cooperative Study 391 Group. Value of fibrosis markers for staging liver fibrosis in patients with precirrhotic alcoholic liver disease. Alcohol Clin Exp Res 2008; 32 (06) 1031-1039
• 86 Voican CS, Louvet A, Trabut JB. et al. Transient elastography alone and in combination with FibroTest^® for the diagnosis of hepatic fibrosis in alcoholic liver disease. Liver Int 2017; 37 (11) 1697-1705
• 87 Aubé C, Oberti F, Korali N. et al. Ultrasonographic diagnosis of hepatic fibrosis or cirrhosis. J Hepatol 1999; 30 (03) 472-478
• 88 Colli A, Fraquelli M, Andreoletti M, Marino B, Zuccoli E, Conte D. Severe liver fibrosis or cirrhosis: accuracy of US for detection—analysis of 300 cases. Radiology 2003; 227 (01) 89-94
• 89 Thiele M, Detlefsen S, Sevelsted Møller L. et al. Transient and 2-dimensional shear-wave elastography provide comparable assessment of alcoholic liver fibrosis and cirrhosis. Gastroenterology 2016; 150 (01) 123-133
• 90 Pavlov CS, Casazza G, Nikolova D. et al. Transient elastography for diagnosis of stages of hepatic fibrosis and cirrhosis in people with alcoholic liver disease. Cochrane Database Syst Rev 2015; 1 (01) CD010542
• 91 Gelsi E, Dainese R, Truchi R. et al. Effect of detoxification on liver stiffness assessed by Fibroscan® in alcoholic patients. Alcohol Clin Exp Res 2011; 35 (03) 566-570
• 92 Nahon P, Kettaneh A, Tengher-Barna I. et al. Assessment of liver fibrosis using transient elastography in patients with alcoholic liver disease. J Hepatol 2008; 49 (06) 1062-1068
• 93 Bardou-Jacquet E, Legros L, Soro D. et al. Effect of alcohol consumption on liver stiffness measured by transient elastography. World J Gastroenterol 2013; 19 (04) 516-522
• 94 Fuster D, Garcia-Calvo X, Zuluaga P. et al. Ultrasound findings of liver damage in a series of patients consecutively admitted for treatment of alcohol use disorder. Drug Alcohol Depend 2018; 190: 195-199
• 95 Cusi K, Isaacs S, Barb D. et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: co-sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract 2022; 28 (05) 528-562
• 96 Kjaergaard M, Lindvig KP, Thorhauge KH. et al. Screening for fibrosis promotes lifestyle changes: a prospective cohort study in 4796 individuals. Clin Gastroenterol Hepatol 2024; 22 (05) 1037-1047.e9
• 97 Palacio-Vieira J, Segura L, Anderson P. et al. Improving screening and brief intervention activities in primary health care: secondary analysis of professional accuracy based on the AUDIT-C. J Eval Clin Pract 2018; 24 (02) 369-374
• 98 Avitabile E, Gratacós-Ginès J, Pérez-Guasch M. et al. Liver fibrosis screening increases alcohol abstinence. JHEP Rep Innov Hepatol 2024; 6 (10) 101165
• 99 Asphaug L, Thiele M, Krag A, Melberg HO. Cost-effectiveness of noninvasive screening for alcohol-related liver fibrosis. Hepatology 2020; 71 (06) 2093-2104
• 100 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. 2022
• 101 Koob GF, Volkow ND. Neurobiology of addiction: a neurocircuitry analysis. Lancet Psychiatry 2016; 3 (08) 760-773
• 102 Blithikioti C, Miquel L, Batalla A. et al. Cerebellar alterations in cannabis users: a systematic review. Addict Biol 2019; 24 (06) 1121-1137
• 103 Hemrage S, Brobbin E, Deluca P, Drummond C. Efficacy of psychosocial interventions to reduce alcohol use in comorbid alcohol use disorder and alcohol-related liver disease: a systematic review of randomized controlled trials. Alcohol Alcohol 2023; 58 (05) 478-484
• 104 Kelly JF, Humphreys K, Ferri M. Alcoholics Anonymous and other 12-step programs for alcohol use disorder. Cochrane Database Syst Rev 2020; 3 (03) CD012880
• 105 O'Farrell TJ, Clements K. Review of outcome research on marital and family therapy in treatment for alcoholism. J Marital Fam Ther 2012; 38 (01) 122-144
• 106 Goldberg SB, Tucker RP, Greene PA. et al. Mindfulness-based interventions for psychiatric disorders: a systematic review and meta-analysis. Clin Psychol Rev 2018; 59: 52-60
• 107 Barrio P, Teixidor L, Ortega L, Balcells M, Vieta E, Gual A. Patients' knowledge and attitudes towards regular alcohol urine screening: a survey study. J Addict Med 2017; 11 (04) 300-307
• 108 Barrio P, Teixidor L, Ortega L. et al. Filling the gap between lab and clinical impact: an open randomized diagnostic trial comparing urinary ethylglucuronide and ethanol in alcohol dependent outpatients. Drug Alcohol Depend 2018; 183: 225-230
• 109 Kuchipudi V, Hobein K, Flickinger A, Iber FL. Failure of a 2-hour motivational intervention to alter recurrent drinking behavior in alcoholics with gastrointestinal disease. J Stud Alcohol 1990; 51 (04) 356-360
• 110 Weinrieb RM, Van Horn DHA, Lynch KG, Lucey MR. A randomized, controlled study of treatment for alcohol dependence in patients awaiting liver transplantation. Liver Transpl 2011; 17 (05) 539-547
• 111 Rolland B, Simon N, Franchitto N, Aubin HJ. France grants an approval to baclofen for alcohol dependence. Alcohol Alcohol 2020; 55 (01) 44-45
• 112 Biso L, Spini A, Petragnano F, Maggio R, Scarselli M, Carli M. Long-term efficacy and safety of sodium oxybate in treating alcohol use disorder: a systematic review and meta-analysis. Curr Neuropharmacol 2024. Epub ahead of print. Doi: 10.2174/1570159 × 22666240902100058
• 113 Guiraud J, Addolorato G, Aubin HJ. et al. Sodium oxybate for alcohol dependence: a network meta-regression analysis considering population severity at baseline and treatment duration. Alcohol Alcohol 2023; 58 (02) 125-133
• 114 Phimarn W, Sakhancord R, Paitoon P, Saramunee K, Sungthong B. Efficacy of varenicline in the treatment of alcohol dependence: an updated meta-analysis and meta-regression. Int J Environ Res Public Health 2023; 20 (05) 4091
• 115 Gratacós-Ginès J, Bruguera P, Pérez-Guasch M. et al. Medications for alcohol use disorder promote abstinence in alcohol-associated cirrhosis: results from a systematic review and meta-analysis. Hepatology 2024; 79 (02) 368-379
• 116 Avanceña ALV, Miller N, Uttal SE, Hutton DW, Mellinger JL. Cost-effectiveness of alcohol use treatments in patients with alcohol-related cirrhosis. J Hepatol 2021; 74 (06) 1286-1294
• 117 Rogal S, Youk A, Zhang H. et al. Impact of alcohol use disorder treatment on clinical outcomes among patients with cirrhosis. Hepatology 2020; 71 (06) 2080-2092
• 118 Ayyala D, Bottyan T, Tien C. et al. Naltrexone for alcohol use disorder: hepatic safety in patients with and without liver disease. Hepatol Commun 2022; 6 (12) 3433-3442
• 119 Thompson R, Taddei T, Kaplan D, Rabiee A. Safety of naltrexone in patients with cirrhosis. JHEP Rep Innov Hepatol 2024; 6 (07) 101095
• 120 Forns X, Caballería J, Bruguera M. et al. Disulfiram-induced hepatitis. Report of four cases and review of the literature. J Hepatol 1994; 21 (05) 853-857
• 121 Ranek L, Buch Andreasen P. Disulfiram hepatotoxicity. BMJ 1977; 2 (6079) 94-96
• 122 Vannier AGL, Shay JES, Fomin V. et al. Incidence and progression of alcohol-associated liver disease after medical therapy for alcohol use disorder. JAMA Netw Open 2022; 5 (05) e2213014
• 123 Kirsch DE, Belnap MA, Burnette EM, Grodin EN, Ray LA. Pharmacological treatments for alcohol use disorder: considering the role of sex and gender. Curr Addict Rep 2024; 11 (01) 81-93
• 124 Fregni F, El-Hagrassy MM, Pacheco-Barrios K. et al; Neuromodulation Center Working Group. Evidence-based guidelines and secondary meta-analysis for the use of transcranial direct current stimulation in neurological and psychiatric disorders. Int J Neuropsychopharmacol 2021; 24 (04) 256-313
• 125 Wolstenholme JT, Duong NK, Brocato ER, Bajaj JS. Gut-liver-brain axis and alcohol use disorder: treatment potential of fecal microbiota transplantation. Alcohol Res 2024; 44 (01) 01
• 126 Aubin HJ, Berlin I, Guiraud J. et al. Prazosin and cyproheptadine in combination in the treatment of alcohol use disorder: a randomized, double-blind, placebo-controlled trial. Addiction 2024; 119 (07) 1211-1223
• 127 Goldfine CE, Tom JJ, Im DD. et al. The therapeutic use and efficacy of ketamine in alcohol use disorder and alcohol withdrawal syndrome: a scoping review. Front Psychiatry 2023; 14: 1141836
• 128 Bogenschutz MP, Ross S, Bhatt S. et al. Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry 2022; 79 (10) 953-962
• 129 Nicholas CR, Wang JB, Coker A. et al. The effects of MDMA-assisted therapy on alcohol and substance use in a phase 3 trial for treatment of severe PTSD. Drug Alcohol Depend 2022; 233: 109356
• 130 Markus W, de Weert-van Oene GH, Becker ES, DeJong CA. A multi-site randomized study to compare the effects of Eye Movement Desensitization and Reprocessing (EMDR) added to TAU versus TAU to reduce craving and drinking behavior in alcohol dependent outpatients: study protocol. BMC Psychiatry 2015; 15 (01) 51
• 131 Balcells-Oliveró MM, Nuño L, Freixa N. et al. Shared reflection to maximize resources and minimize costs: the reflecting team applied to a hospital environment. Community Ment Health J 2021; 57 (04) 746-752
• 132 Johansson M, Romero D, Jakobson M, Heinemans N, Lindner P. Digital interventions targeting excessive substance use and substance use disorders: a comprehensive and systematic scoping review and bibliometric analysis. Front Psychiatry 2024; 15: 1233888
• 133 Caballeria E, Maier M, Balcells-Oliveró M. et al. Rehabilitation gaming system for alcohol-related cognitive impairment: a pilot usability study. Alcohol Alcohol 2022; 57 (05) 595-601
• 134 Gamito P, Oliveira J, Matias M. et al. Virtual reality cognitive training among individuals with alcohol use disorder undergoing residential treatment: pilot randomized controlled trial. J Med Internet Res 2021; 23 (01) e18482
• 135 Perski O, Keller J, Kale D. et al. Understanding health behaviours in context: a systematic review and meta-analysis of ecological momentary assessment studies of five key health behaviours. Health Psychol Rev 2022; 16 (04) 576-601
• 136 Perski O, Hébert ET, Naughton F, Hekler EB, Brown J, Businelle MS. Technology-mediated just-in-time adaptive interventions (JITAIs) to reduce harmful substance use: a systematic review. Addiction 2022; 117 (05) 1220-1241
• 137 Caballeria E, Balcells-Oliveró M, Bataller R. et al. Multiplatform web app (My Way Up) plus motivational interviewing for improving treatment retention in patients with onset of alcohol-related liver disease and alcohol use disorder—an example of participatory research. Digit Health 2024; 10: 20 552076241242787
• 138 Lau HM, Smit JH, Fleming TM, Riper H. Serious games for mental health: are they accessible, feasible, and effective? A systematic review and meta-analysis. Front Psychiatry 2017; 7 (JAN): 209
• 139 Louvet A, Bourcier V, Archambeaud I. et al; CIRRAL group. Low alcohol consumption influences outcomes in individuals with alcohol-related compensated cirrhosis in a French multicenter cohort. J Hepatol 2023; 78 (03) 501-512
• 140 Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption–II. Addiction 1993; 88 (06) 791-804
• 141 Donnadieu-Rigole H, Olive L, Nalpas B. et al. Follow-up of alcohol consumption after liver transplantation: interest of an addiction team?. Alcohol Clin Exp Res 2017; 41 (01) 165-170
• 142 Marti-Aguado D, Clemente-Sanchez A, Bataller R. Cigarette smoking and liver diseases. J Hepatol 2022; 77 (01) 191-205
• 143 Alvarado-Tapias E, Marti-Aguado D, Kennedy K. et al. Bariatric surgery is associated with alcohol-related liver disease and psychiatric disorders associated with AUD. Obes Surg 2023; 33 (05) 1494-1505
• 144 Alvarado-Tapias E, Martí-Aguado D, Gómez-Medina C. et al. Binge drinking at time of bariatric surgery is associated with liver disease, suicides, and increases long-term mortality. Hepatol Commun 2024; 8 (08) e0490
• 145 Chuong V, Farokhnia M, Khom S. et al. The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission. JCI Insight 2023; 8 (12) e170671
• 146 Jensen EL, Israelsen M, Krag A. Transforming steatotic liver disease management: the emerging role of GLP-1 receptor agonists. Hepatol Commun 2024; 8 (11) e0561
• 147 Israelsen M, Madsen BS, Torp N. et al; GALAXY, MicrobLiver Consortia. Rifaximin-α for liver fibrosis in patients with alcohol-related liver disease (GALA-RIF): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Gastroenterol Hepatol 2023; 8 (06) 523-532
• 148 Pose E, Trebicka J, Mookerjee RP, Angeli P, Ginès P. Statins: old drugs as new therapy for liver diseases?. J Hepatol 2019; 70 (01) 194-202
• 149 Sharma R, Simon TG, Hagström H. et al. Statins are associated with a decreased risk of severe liver disease in individuals with noncirrhotic chronic liver disease. Clin Gastroenterol Hepatol 2024; 22 (04) 749-759.e19
• 150 Bang UC, Benfield T, Bendtsen F. Reduced risk of decompensation and death associated with use of statins in patients with alcoholic cirrhosis. A nationwide case-cohort study. Aliment Pharmacol Ther 2017; 46 (07) 673-680
• 151 Newsome PN, Buchholtz K, Cusi K. et al; NN9931-4296 Investigators. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med 2021; 384 (12) 1113-1124
• 152 Yen FS, Hou MC, Cheng-Chung Wei J. et al. Glucagon-like peptide-1 receptor agonist use in patients with liver cirrhosis and type 2 diabetes. Clin Gastroenterol Hepatol 2024; 22 (06) 1255-1264.e18
• 153 Simon TG, Patorno E, Schneeweiss S. Glucagon-like peptide-1 receptor agonists and hepatic decompensation events in patients with cirrhosis and diabetes. Clin Gastroenterol Hepatol 2022; 20 (06) 1382-1393.e19
• 154 Wang W, Volkow ND, Berger NA, Davis PB, Kaelber DC, Xu R. Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population. Nat Commun 2024; 15 (01) 4548
• 155 Lähteenvuo M, Tiihonen J, Solismaa A, Tanskanen A, Mittendorfer-Rutz E, Taipale H. Repurposing semaglutide and liraglutide for alcohol use disorder. JAMA Psychiatry 2025; 82 (01) 94-98
• 156 Stefanakis K, Kokkorakis M, Mantzoros CS. The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation. Metabolism 2024; 161: 156057
• 157 Talukdar S, Owen BM, Song P. et al. FGF21 regulates sweet and alcohol preference. Cell Metab 2016; 23 (02) 344-349
• 158 Harrison SA, Frias JP, Neff G. et al; HARMONY Study Group. Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Gastroenterol Hepatol 2023; 8 (12) 1080-1093
• 159 Loomba R, Sanyal AJ, Kowdley KV. et al. Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH. N Engl J Med 2023; 389 (11) 998-1008
• 160 Flippo KH, Trammell SAJ, Gillum MP. et al. FGF21 suppresses alcohol consumption through an amygdalo-striatal circuit. Cell Metab 2022; 34 (02) 317-328.e6
• 161 Nakajima T, Kamijo Y, Tanaka N. et al. Peroxisome proliferator-activated receptor alpha protects against alcohol-induced liver damage. Hepatology 2004; 40 (04) 972-980
• 162 Xu Y, Denning KL, Lu Y. PPARα agonist WY-14,643 induces the PLA2/COX-2/ACOX1 pathway to enhance peroxisomal lipid metabolism and ameliorate alcoholic fatty liver in mice. Biochem Biophys Res Commun 2022; 613: 47-52
• 163 Chu H, Jiang L, Gao B. et al. The selective PPAR-delta agonist seladelpar reduces ethanol-induced liver disease by restoring gut barrier function and bile acid homeostasis in mice. Transl Res 2021; 227: 1-14
• 164 Koizumi A, Kaji K, Nishimura N. et al. Effects of elafibranor on liver fibrosis and gut barrier function in a mouse model of alcohol-associated liver disease. World J Gastroenterol 2024; 30 (28) 3428-3446